Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals extends $1.9 billion term loan to 2033, cuts margin 50 basis points

Neutral Impact 3 of 5 financing Written later

Jazz Pharmaceuticals' subsidiary Jazz Financing Lux entered into Amendment No. 4 to its credit agreement on September 23, 2026, extending the maturity of the $1.9 billion Tranche B-2 dollar term loan from May 5, 2028 to May 5, 2033 and lowering its interest margin. The filing does not include new earnings, guidance, or changes to operations, so the effect on shareholders depends on the lower borrowing cost and longer repayment schedule.

Key points

  • Maturity extended from May 5, 2028 to May 5, 2033 for the Tranche B-3 dollar term loans
  • Applicable margin cut 50 basis points to 1.75% for Term SOFR borrowings and 0.75% for prime rate borrowings, with a 0.50% Term SOFR floor
  • Principal outstanding of $1,895,000,000 before and after the amendment; Jazz Lux also borrowed $273,310,355.18 in additional term loans to repay non-converted loans
  • Quarterly amortization of 0.25% of initial principal, with the remaining balance due May 5, 2033

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECSep 23, 2026, 4:15 PM ET
Accession number0001193125-26-399425

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.